• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Richard Branson double-booked his own job interview. The candidate stuck in traffic with him for 2.5 hours is now Virgin's CEO

2

IBM’s CEO disagrees with JPMorgan CEO Jamie Dimon’s disdain for texting in meetings: ‘Telling people they can't use their technology would be weird’

3

Tech billionaires and executives like Evan Spiegel and Peter Thiel are publicly shielding their children from the products that made them rich

1

Richard Branson double-booked his own job interview. The candidate stuck in traffic with him for 2.5 hours is now Virgin's CEO

2

IBM’s CEO disagrees with JPMorgan CEO Jamie Dimon’s disdain for texting in meetings: ‘Telling people they can't use their technology would be weird’

3

Tech billionaires and executives like Evan Spiegel and Peter Thiel are publicly shielding their children from the products that made them rich
FinanceMartin Shkreli

Accused Pharma CEO Martin Shkreli: ‘My Investors Made Lots Of Money’

By
Jen Wieczner
Jen Wieczner
Down Arrow Button Icon
By
Jen Wieczner
Jen Wieczner
Down Arrow Button Icon
December 18, 2015, 12:09 AM ET
Turing Pharmaceutical CEO Martin Shkreli Arrested For Securities Fraud
NEW YORK, NY - DECEMBER 17: Martin Shkreli (C), CEO of Turing Pharmaceutical, is brought out of 26 Federal Plaza by law enforcement officials after being arrested for securities fraud on December 17, 2015 in New York City. Shkreli gained notoriety earlier this year for raising the price of Daraprim, a medicine used to treat the parasitic condition of toxoplasmosis, from $13.50 to $750 though the arrest that happened early this morning does not involve that price hike. (Photo by Andrew Burton/Getty Images)Photograph by Andrew Burton Getty Images
Add Fortune on Google for similar content.

Some 13 hours after his arrest by the FBI in New York Thursday morning, Martin Shkreli denied all the government’s accusations against him, including that he used his hedge fund and biotech company “like a Ponzi scheme.”

Shkreli, the CEO of Turing Pharmaceuticals, suggested that the federal charges of securities fraud and conspiracy amounted to an unfair attempt to punish him for his unrelated and more recent decision to hike the price of a drug 5,000% overnight. That, along with off-color behavior and comments about wishing he had raised the drug’s price even higher, as well as about Taylor Swift and the Wu-Tang Clan (among other subjects), earned him widespread public ire.

The federal indictment and additional complaint by the Securities and Exchange Commission made public Thursday allege that Shkreli pillaged the previous biotech company he founded, Retrophin (RTRX), to pay back the hedge fund investors whose money he’d lost entirely. But Shkreli denied that he was operating a Ponzi scheme, as one U.S. attorney had described it. Instead, Shkreli claimed, he successfully made money for his investors.

“Ponzi victims do not make money, yet Mr. Shkreli’s investors enjoyed strong results,” a spokesman for Shkreli said in a statement. Asked to quantify the investment returns Shkreli delivered to his shareholders, and whether the profits included funds that Shkreli allegedly misappropriated from Retrophin, the spokesman could not immediately comment. (Fortune will add any responses it receives.) In August, Retrophin sued Shkreli separately over similar accusations after firing him as CEO.

In retorting the government’s accusations Thursday evening, Shkreli also insinuated that the financial transactions in question were simply over the heads of less sophisticated regulators, as they “involve complex accounting matters that the [New York federal prosecutors] and SEC fail to understand,” the spokesman said.

Shkreli was released Thursday afternoon after posting $5 million bail. Apparently his freedom was worth paying the steep fee, according to a message he posted on Twitter:

Glad to be home. Thanks for the support.

— Martin Shkreli (e/acc) (@MartinShkreli) December 18, 2015

Here’s an extended excerpt of Shkreli’s official statement:

It is no coincidence that these charges, the result of investigations which have been languishing for considerable time, have been filed at the same time of Shkreli’s high-profile, controversial and yet unrelated activities. At a press conference, the government suggested that Mr. Shkreli was involved in a Ponzi scheme. Ponzi victims do not make money, yet Mr. Shkreli’s investors enjoyed strong results. In summary, Mr. Shkreli expects to be fully vindicated.

About the Author
By Jen Wieczner
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Finance


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in Finance


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.